The DOI matches its Crossref record; 156 of the 157 references it cites were found in a registry or an index.
Serotonin–dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias
Abstract
Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, other brain regions are probably also involved because L-DOPA-induced AIMs occur via integrative changes in multiple neurotransmitter systems throughout the CNS, including those present in the striatum, globus pallidus, thalamus, cortical areas, subthalamic nucleus, and cerebellum (Carta et al., 2008;Fox et al., 2008).”
From Nicotinic receptor-mediated reduction in l-DOPA-induced dyskinesias may occur via desensitization (2010) · cites this paper as Carta et al., 2008
Citations
Cites
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Steinbusch, H. W. M. (1981) · Neuroscience · doi:10.1016/0306-4522(81)90146-9 · Cited by 2,415
Molecular, pharmacological and functional diversity of 5-HT receptors
Hoyer, D., Hannon, J. P., & Martin, G. R. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(01)00746-8 · Cited by 1,898
Ahlskog, J. E., & Muenter, M. D. (2001) · Movement Disorders · doi:10.1002/mds.1090 · Cited by 1,456
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
Description of Parkinson's Disease as a Clinical Syndrome
Fahn, S. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07458.x · Cited by 979
Langston, J. W., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
Dopamine-mediated regulation of corticostriatal synaptic plasticity
Calabresi, P., Picconi, B., Tozzi, A., & Di Filippo, M. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.001 · Cited by 865
Electrophysiological responses of serotoninergic dorsal raphe neurons to 5‐HT1A and 5‐HT1B agonists
Sprouse, J. S., & Aghajanian, G. K. (1987) · Synapse · doi:10.1002/syn.890010103 · Cited by 848
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821
Cited by
Sorted by citations
Items 101–131 of 131
l -DOPA and graft-induced dyskinesia: Different treatment, same story?
Breger, L. S., & Lane, E. L. (2013) · Experimental Biology and Medicine · doi:10.1177/1535370213488478 · Cited by 7
Chen, Y.-H., Kuo, T., Wang, V., Cheng, P.-W., Huang, E. Y., Ma, K., Greig, N. H., Olson, L., Hoffer, B. J., & Tseng, K.-Y. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240080 · Cited by 6
Modulation of the Generation of Dopaminergic Neurons from Human Neural Stem Cells by Bcl-XL
Martı́nez-Serrano, A., Castillo, C. G., Courtois, E. T., García-García, E., & Liste, I. (2011) · Vitamins and hormones · doi:10.1016/b978-0-12-386015-6.00029-9 · Cited by 5
Calderón, V., Luna-Leal, A., Gómez-Paz, A., Ramirez‐López, F., Arias-García, M. A., Lara‐González, E., Galarraga, E., & Bargas, J. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.03.036 · Cited by 5
Mathematical Models: Interactions Between Serotonin and Dopamine in Parkinson’s Disease
Best, J. A., Oakley, G., Reed, M. C., & Frederik, H. (2011) · InTech eBooks · doi:10.5772/19897 · Cited by 5
Muddapu, V. R., Vijayakumar, K., Ramakrishnan, K., & Chakravarthy, V. S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.05.026807 · Cited by 5
Zimmer, L., & Newman‐Tancredi, A. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110267 · Cited by 4
Silkis, I. G. (2014) · Neurochemical Journal · doi:10.1134/s1819712414030118 · Cited by 4
Understanding and Prevention of “Therapy-” Induced Dyskinesias
Avilés-Olmos, I., Kefalopoulou, Z. M., & Foltynie, T. (2012) · Parkinson s Disease · doi:10.1155/2012/640815 · Cited by 4
Budrow, C., Bernal-Conde, L. D., Sandoval, I. M., Galfano, A., Grezenko, H., Velazquez, A., Marmion, D. J., Flores-Barrera, E., Venkatesh, S., Coyle, M., et al. (2026) · Acta Neuropathologica Communications · doi:10.1186/s40478-026-02221-1 · Cited by 2
Si, Q., Gan, C., Cao, X., Shi, J., Yu, S., Sun, H., Wang, X., Wang, X., Wang, G., Yuan, Y., et al. (2025) · Neurology and Therapy · doi:10.1007/s40120-025-00823-w · Cited by 2
Tomiyama, K., Kato, R., Hara, Y., Kobayashi, M., Mishina, M., Yanagawa, Y., Kinsella, A., Koshikawa, N., & Waddington, J. L. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.07.038 · Cited by 2
Lazarova, M. I., Tancheva, L. P., Chayrov, R., Tzvetanova, E., Alexandrova, A., Popatanasov, А., Uzunova, D. N., Stefanova, M. O., Stankova, I. G., & Kalfin, R. E. (2022) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01964-x · Cited by 2
Pharmacological Properties of Levodopa
Huot, P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6503-3_9 · Cited by 2
Dyskinesia in Parkinson's Disease Therapy
Carta, A. R., Giuffrida, A., & Fisone, G. (2012) · Parkinson s Disease · doi:10.1155/2012/639080 · Cited by 1
OMICS as Therapeutic Platform: Environmental Factors to Parkinson’s Disease
Kim, H. D., & Warner, S. (2016) · Journal of Microbial & Biochemical Technology · doi:10.4172/1948-5948.1000289 · Cited by 1
Cell Replacement Strategies for Parkinson’s Disease
Chatterjee, D., Wakeman, D. R., & Kordower, J. H. (2017) · Molecular and translational medicine · doi:10.1007/978-3-319-57153-9_4 · Cited by 1
Stem Cell-Based Therapies for Parkinson’s Disease
Palmer, C., & Liste, I. (2017) · Stem cells in clinical applications · doi:10.1007/978-3-319-33720-3_5 · Cited by 1
Functional Anatomy of the Motor and Non‐Motor Circuitry of the Basal Ganglia
Smith, Y. (2011) · Parkinson s Disease · doi:10.1002/9781444397970.ch4 · Cited by 1
Muddapu, V. R., Vijayakumar, K., Ramakrishnan, K., & Chakravarthy, V. S. (2020) · arXiv (Cornell University) · doi:10.48550/arxiv.2004.08320 · Cited by 1
Basal Ganglia Circuitry Models of Levodopa-Induced Dyskinesia
Ko, W. K. D., Bastide, M. F., & Bézard, E. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6503-3_7
Anatomy and Synaptic Connectivity of the Basal Ganglia
Smith, Y. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4160-5316-3.00074-5
Imaging of Dopamine and Serotonin Receptors and Transporters
Felicio, A. C., & Stoessl, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418677-4.00010-5
Investigating chondroitin sulphate proteoglycans as a therapeutic target for Parkinson's disease
Fletcher, E. J. R. (2017) · Research Portal (King's College London)
A study on candidate gene polymorphisms in association with mental retardation
Bhowmik, A. D. (2010) · Shodhganga
Wichit, P., Bongsebandhu-phubhakdi, S., Bhidayasiri, R., & Phokaewvarangkul, O. (2019) · doi:10.58837/chula.the.2019.366
Mansouri-Guilani, N. (2017) · theses.fr (ABES) · doi:10.70675/99ced3b5zeac6z4eb2z8e6cz01bcad7cf2d9
Neuroinflammation in levodopa-induced dyskinesia in Parkinson’s disease: current state of the art
Santos‐Lobato, B. L., de Souza, T. P., Correa, L. V. D. S., Gomes, M. Z., Bel, E. A. D., & Tumas, V. (2026) · Journal of Neural Transmission · doi:10.1007/s00702-026-03317-7
Metadata
- Authors
- CARTA, M., CARLSSON, T., MUNOZ, A., KIRIK, D., & BJORKLUND, A.
- Affiliations
- Lund University (SE)
- Corresponding author
- CARTA, M
- Venue
- Progress in brain research
- Publisher
- Elsevier
- Published
- 2008
- Volume
- 172
- Pages
- 465-478
- ISSN
- 0079-6123 (ISSN-L)
- OpenAlex
- W1933235205
- Cited by
- 131
- References
- 157
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 6 · 2022: 8 · 2021: 4 · 2020: 8 · 2019: 2 · 2018: 2 · 2017: 6 · 2016: 6 · 2015: 6 · 2014: 13 · 2013: 14 · 2012: 11
- FWCI
- 37.83
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Progress in brain research (publishedVersion)
- PubMed (publishedVersion)
- UNICA IRIS Institutional Research Information System (University of Cagliari) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- serotonin, dopamine, levodopa-induced dyskinesia, Parkinson's disease, serotonergic system, serotonergic neurons, treatment options
- MeSH terms
- Animals, Clinical Trials as Topic, Dopamine, Dyskinesia, Drug-Induced, Humans, Levodopa, Parkinson Disease, Receptors, Dopamine, Receptors, Serotonin, Serotonin, Presynaptic Terminals, Protein Isoforms, Parkinsonian Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
